Totals
- Total revenue
- $3,836,237
- Total expenses
- $2,887,928
- Contributions and grants received
- $3,633,246
- Grants paid
- $1,573,518
- Program service revenue
- $22,946
- Investment income
- $169,075
- Other revenue
- $10,970
- Total assets, end of year
- $6,855,964
- Total liabilities, end of year
- $383,012
- Net assets or fund balances, end of year
- $6,472,952
- Program services expenses (Part IX)
- $2,654,711
- Management and general expenses
- $183,244
- Fundraising expenses
- $49,973
- Program service expenses (Part III)
- $2,654,711
Program services were 91.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1c · Fundraising events
$79,378
-
1f · All other contributions, gifts and grants
$3,553,868
-
2a · Program service revenue: SUMMIT TICKETS
total $22,946 · related or exempt $22,946
-
3 · Investment income
total $170,108 · excluded $170,108
-
7a · Gross sales of assets other than inventory
securities $64,684
-
7b · Less cost or other basis and sales expenses
securities $65,717
-
7c · Gain or loss
securities -$1,033
-
7d · Net gain or loss
total -$1,033 · excluded -$1,033
-
8a · Fundraising events: gross income
$32,295
-
8a · Fundraising events: contributions included on line 1c
$79,378
-
8b · Fundraising events: direct expenses
$33,222
-
8c · Net income from fundraising events
total -$927 · excluded -$927
-
11a · Other revenue: MISCELLANEOUS INCOME
total $11,897 · related or exempt $11,897
-
11e · Other revenue, total
$11,897
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $1,573,518 · program services $1,573,518
-
5 · Compensation of officers, directors and key employees
total $240,410 · program services $191,787 · management and general $28,539 · fundraising $20,084
-
7 · Other salaries and wages
total $227,887 · program services $181,797 · management and general $27,052 · fundraising $19,038
-
8 · Pension plan contributions
total $2,129 · program services $1,698 · management and general $253 · fundraising $178
-
9 · Other employee benefits
total $11,817 · program services $9,427 · management and general $1,403 · fundraising $987
-
10 · Payroll taxes
total $43,696 · program services $34,859 · management and general $5,187 · fundraising $3,650
-
11c · Fees: accounting
total $57,782 · management and general $57,782
-
11g · Fees: other
total $6,878 · program services $6,002 · management and general $813 · fundraising $63
-
12 · Advertising and promotion
total $3,879 · fundraising $3,879
-
13 · Office expenses
total $399 · program services $383 · management and general $12 · fundraising $4
-
14 · Information technology
total $69,313 · program services $67,330 · management and general $1,652 · fundraising $331
-
17 · Travel
total $63,600 · program services $63,201 · fundraising $399
-
19 · Conferences, conventions and meetings
total $6,807 · program services $6,807
-
20 · Interest
total $800 · management and general $800
-
22 · Depreciation, depletion and amortization
total $28,342 · program services $27,209 · management and general $850 · fundraising $283
-
23 · Insurance
total $5,394 · program services $4,647 · management and general $699 · fundraising $48
-
24a · Other expenses: PROGRAM SUPPLIES
total $426,733 · program services $426,733
-
24b · Other expenses: BANK FEES
total $44,703 · management and general $44,703
-
24c · Other expenses: LICENSES AND FEES
total $23,851 · program services $22,896 · management and general $716 · fundraising $239
-
24d · Other expenses: DUES AND SUBSCRIPTIONS
total $15,835 · program services $7,544 · management and general $8,251 · fundraising $40
-
24e · All other expenses
total $34,155 · program services $28,873 · management and general $4,532 · fundraising $750
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $1,547,913 · end of year $1,780,753
-
2 · Savings and temporary cash investments
beginning of year $3,005,670 · end of year $4,765,386
-
3 · Pledges and grants receivable
beginning of year $588,902 · end of year $166,408
-
4 · Accounts receivable
beginning of year $4,000 · end of year $480
-
9 · Prepaid expenses and deferred charges
beginning of year $51,071 · end of year $54,597
-
11 · Investments: publicly traded securities
beginning of year $8,766
-
14 · Intangible assets
beginning of year $3,312 · end of year $3,312
-
15 · Other assets
beginning of year $407,870 · end of year $85,028
-
17 · Accounts payable and accrued expenses
beginning of year $92,939 · end of year $117,567
-
18 · Grants payable
end of year $265,445
-
27 · Net assets without donor restrictions
beginning of year $3,576,304 · end of year $5,497,789
-
28 · Net assets with donor restrictions
beginning of year $1,948,261 · end of year $975,163
Mission and programs · 2025
Mission
WE ARE A PATIENT-DRIVEN ORGANIZATION SEEKING A CURE AND WORKING TO IMPROVE PATIENTS' QUALITY OF LIFE AND LIFE EXPECTANCY WORLDWIDE.
Activities or mission (Part I)
WE ARE A PATIENT-DRIVEN ORGANIZATION SEEKING A CURE AND WORKING TO (CONTINUED ON SCHEDULE O)IMPROVE PATIENTS' QUALITY OF LIFE AND LIFE EXPECTANCY WORLDWIDE.
-
ALK POSITIVE, INC. IS A PATIENT DRIVEN 501(C)(3) NONPROFIT CORPORATION PROVIDING SUPPORT, EMPATHY, AND RESEARCH FUNDING TO CHANGE THE FUTURE FOR ALK-POSITIVE CANCER PATIENTS. ALK-POSITIVE CANCER IS ESTIMATED TO OCCUR IN APPROXIMATELY 100,000 PATIENTS WORLDWIDE EVERY YEAR. ALTHOUGH THE VAST MAJORITY OF CASES OCCUR AS LUNG CANCER, IT CAN ALSO ORIGINATE IN MANY OTHER ORGANS. THE MEDIAN AGE FOR ALK-POSITIVE PATIENTS AT DIAGNOSIS IS ABOUT 50 YEARS WITH MANY IN THEIR FORTIES, THIRTIES AND EVEN YOUNGER. APPROXIMATELY 55% OF ALK-POSITIVE PATIENTS ARE FEMALE AND THE DISEASE OCCURS WITH PEOPLE OF ALL RACES.(CONTINUED ON SCHEDULE O)IN 2017, SOME ALK-POSITIVE CANCER PATIENTS AND CAREGIVERS FORMED THE OUTREACH MANAGEMENT GROUP TO PARTNER WITH THE LUNGEVITY FOUNDATION IN ORDER TO RAISE FUNDS FOR CANCER RESEARCH. IN 2018, THE PARTNERSHIP WAS FORMALIZED INTO A JOINT FUNDRAISING AND RESEARCH AGREEMENT WITH BOTH LUNGEVITY AND THE GO2 FOUNDATION FOR LUNG CANCER. FROM 2017 TO 2021, THE PARTNERSHIPS GENERATED OVER $4.7M IN CONTRIBUTIONS AND AWAREDED $2.8M IN TRANSLATIONAL RESEARCH GRANTS WITH THE PURPOSE OF IMPROVING ALK-POSITIVE CANCER PATIENT OUTCOMES. BY MARCH 2021, THE OUTREACH MANAGEMENT GROUP HAD INCORPORATED AND WAS RECOGNIZED BY THE IRS AS A 501(C)(3) NON PROFIT ORGANIZATION CALLED ALK POSITIVE INC. DURING 2021-22 ANOTHER $3.4M IN CONTRIBUTIONS WAS GENEROUSLY RAISED WITH RESEARCH GRANTS TOTALING $2.6M AWARDED. ALSO IN 2022, THE FIRST TWO EMPLOYEES WERE HIRED - A DIRECTOR OF RESEARCH AND CLINICAL AFFAIRS AND AN EXECUTIVE DIRECTOR.BY FAR, THE MOST EFFECTIVE TREATMENTS FOR ALK-POSITIVE CANCER ARE THE ROAL ALK TYROSINE KINASE INHIBITORS (TKI'S). THESE ARE NOW FDA APPROVED IN 1ST, 2ND AND 3RD GENERATION VERSIONS, EACH GENERATION MORE EFFECTIVE THAN THE PREVIOUS. HOWEVER, WHILE TKI'S HAVE IMPROVED MEDIAN OVERALL SURVIVAL FROM A FEW MONTHS TO MANY YEARS, ALK-POSITIVE CANCERS INEVITABLY MUTATE AND BECOME RESISTANT TO ALL TKI'S. THE ORGANIZATION CREATED THE RESEARCH REVIEW PANEL (COMMITTEE) COMPRISING VOLUNTEER ALK-POSITIVE CANCER PATIENTS, CAREGIVERS AND WORLD-RENOWNED SCIENTIFIC AND RESEARCH EXPERTS TO HELP REVIEW AND AWARD THE MOST PROMISING ALK-POSITIVE CANCER RESEARCH PROJECTS TO IMPROVE PATIENT OUTCOMES. IN 2022, THIS RESERACH TEAM WAS EXPANDED TO:-RESEARCH ACCELERATION COMMITTEE: ACCELERATE ACADEMIC AND BIOTECH RESEARCH THAT LEADS TO NEW THERAPIES FOR ALK-POSITIVE PATIENTS, INCLUDING IMMUNOTHERAPIES AND COMBINATION THERAPIES, AND NEW CLINICAL TRIALS, VIA COLLABORATION WITH ACADEMIA, INDUSTRY AND VENTURE CAPITAL.-CLINICAL TRIALS COMMITTEE: COLLABORATE WITH ACADEMIA AND INDUSTRY TO DEVELOP NEW FRAMEWORKS FOR CLINICAL TRIALS AND TO ACCELERATE CREATION, EFFECTIVE ENROLLMENT AND SUCCESSFUL READOUTS FOR CLINICAL TRIALS INVOLVING AND BENEFICIAL TO ALK-POSITIVE PATIENTS.-TRANSLATIONAL INVESTIGATIONS GROUP: FRAM AND IMPLEMENT AN INTERNAL ALK-POSITIVE RESEARCH PROGRAM THAT ADDRESSES KEY QUESTIONS FOR WHICH ANSWERS WILL ENABLE THE DEVELOPMENT OF NEW ALK THERAPIES, NIOMARKS OF TREATMENT RESPONSE AND ACCELERATED CLINICAL TRIALS.
Expenses $2,654,711 · Grants $1,573,518 · Revenue $34,843
As filed on the 2025 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
AMANDA BIALACK-STEWART
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 5
-
YVONNE DIAZ
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 5
-
SUMMER FARMEN
VICE PRESIDENT
- Total calculated
- $0
- Hours/week
- 5
-
MARC MUSKAVITCH
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 5
-
JOHN O'SULLIVAN
TREASURER
- Total calculated
- $0
- Hours/week
- 5
-
DUNCAN PREECE
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 5
-
NANCEE PRONSATI
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 5
-
KIRK SMITH
PRESIDENT
- Total calculated
- $0
- Hours/week
- 10
-
JEFFREY STURM
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 5
-
CHRISTINA WEBER
SECRETARY
- Total calculated
- $0
- Hours/week
- 5
-
GREG WEHN
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 5
-
TERESA WIANT
LEGAL CHAIR
- Total calculated
- $0
- Hours/week
- 5
-
KENNETH CULVER
DOR & CLINICAL AFFAIRS, ED 11/25
- Total calculated
- $214,167
- From this org
- $205,600
- From related orgs
- $0
- Other
- $8,567
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $205,600
- Bonus
- $0
- Other
- $0
- Deferred
- $8,567
- Nontaxable benefits
- $0
- Filer's total
- $214,167
-
SUZANNE HOUSSAINY
EXECUTIVE DIRECTOR 1/25-2/25
- Total calculated
- $26,243
- From this org
- $25,456
- From related orgs
- $0
- Other
- $787
- Hours/week
- 40
-
SADIA YAAKOV
MEDICAL TEAM PROJECT MANAGER
- Total calculated
- $132,689
- From this org
- $128,708
- From related orgs
- $0
- Other
- $3,981
- Hours/week
- 40
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
None.
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
COMMONWEALTH CANCER CONSORTIUM
$500,000
RESEARCH AGREEMENT
-
OHIO STATE UNIVERSITY FOUNDATION
$274,620
RESEARCH AGREEMENT
-
RESEARCH AGREEMENT
-
RESEARCH AGREEMENT
-
RESEARCH AGREEMENT
-
LINKS FOR LUNGS ASSISTANCE
-
$52,203
RESEARCH AGREEMENT
-
RESEARCH AGREEMENT
Provenance
- Return type
- form_990
- Tax year
- 2025
- IRS schema version
- 2025v4.2
- Source object
- 202632399349300938
The source document this was parsed from is served over the API, which is where bulk and document access live.